Molecular nodal staging with OSNA

Determining the malignant status of lymph nodes (LN) is an important step in staging cancers because it influences the need and type of surgery and adjuvant therapies.

Frozen section is the most commonly used technique for intraoperative LN assessment, yet it suffers from low sensitivity compared to post-operative pathological examination. The latter is mainly attributed to the low detection rate of micro-metastases and isolated tumour cells. The use of multi-step formalin fixed tissue sections stained by haematoxylin and eosin, with or without, immunohistochemistry increases the detection rate of low volume disease. Nonetheless, a significant number of micro-metastases can still be overlooked because during histological work-up, only small parts of LNs are typically screened. Furthermore, the histology-based technique is often time-consuming and can be subjected to observation error. As such, it is not ideal for intra-operative assessment, especially when a high number of LNs must be investigated. [2]

Analysing lymph node tissue reliably and accurately is therefore crucial for detecting the real metastatic nodal tumour burden and precisely staging cancer patients.

• Accurate whole-node metastatic tumour burden quantification
• Highly sensitive molecular in-vitro diagnostic
• Standardised, objective results thanks to automated analyser
• Fast availability of results (~20min for 1 LN; ~30min for 14 LNs)
• Easy-to-use integrated user interface and ready-to-use reagents
• High flexibility (pan-cancer/ multi-patient)
• Improved patient quality of life with shorter waiting time, less stress and earlier start of adjuvant therapies
• IVDD CE-marked

* licensed under the agreement with Eiken Chemical CO., LTD

OSNA described in one word: Check out the video below to hear it directly from our customers.